In this trial, the carboplatin-VELI arm enrolled 72 patients with HER2-BC, who received Veliparib plus carboplatin during the paclitaxel sequence (VELI-CARBO) followed by doxorubicin and cyclophosphamide (AC). This evidence concerns the gene ERBB2 and breast cancer.